Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2016 - 2024)

Aurinia Pharmaceuticals has reported Other Non-Current Liabilities for 8 years, with the latest figure at $11.1 million in Q4 2024.

• For the quarter ending Q4 2024, Other Non-Current Liabilities rose 1.8% year-over-year to $11.1 million; the trailing twelve-month figure through Dec 2024 stood at $11.1 million (up 1.8% YoY), and the FY2024 full-year result was $11.1 million, up 1.8% from the prior year.
• Other Non-Current Liabilities for Q4 2024 stood at $11.1 million, up from $10.8 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $17.9 million in Q1 2021, with the low at $8.7 million in Q2 2023.
• Historically, Other Non-Current Liabilities has averaged $13.7 million across 5 years, with a median of $12.3 million in 2023.
• Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 162.57% — and 2023, when it sank 46.56%.
• Aurinia Pharmaceuticals' Other Non-Current Liabilities stood at $16.3 million in 2020, then declined by 2.12% to $16.0 million in 2021, then dropped by 23.72% to $12.2 million in 2022, then fell by 10.32% to $10.9 million in 2023, then increased by 1.8% to $11.1 million in 2024.
• The last three Other Non-Current Liabilities figures came in at $11.1 million (Q4 2024), $10.8 million (Q3 2024), and $10.9 million (Q2 2024), per Business Quant data.